Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 4/20 | 0.51 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | PRKACA | P17612 | 3/20 | 0.45 |
| ▸ | PRKCB | P05771 | 2/20 | 0.45 |
| ▸ | PRKCA | P17252 | 2/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705131 | 0.90 | FLT3 (0.67) | FLT3KDRAXLPIM1CAMKK2 | |
| SCHEMBL13596802 | 0.82 | PRKCB (0.72) | FLT3KDRPIM1TGFBR1PDPK1 | |
| SCHEMBL17210880 | 0.79 | PIM1 (0.50) | FLT3KDRAXLPIM1CAMKK2 | |
| SCHEMBL29541048 | 0.79 | FLT3 (0.58) | FLT3KDRPIM1CAMKK2TGFBR1 | |
| SCHEMBL5828735 | 0.77 | PIM1 (0.54) | FLT3KDRAXLPIM1CAMKK2 | |
| SCHEMBL29756414 | 0.76 | PRKCB (0.78) | FLT3KDRPIM1GSK3BCDK2 | |
| SCHEMBL5333315 | 0.76 | PRKCB (0.78) | FLT3KDRPIM1GSK3BCDK2 | |
| SCHEMBL5618155 | 0.76 | TGFBR1 (0.71) | FLT3AXLPIM1CAMKK2TGFBR1 | |
| SCHEMBL5879310 | 0.75 | FLT3 (0.49) | FLT3KDRAXLPIM1CAMKK2 | |
| SCHEMBL19216935 | 0.75 | KDR (0.60) | FLT3KDRPIM1CAMKK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2025-09-18 | — | — | US | disclosed |
| WO-2024077203-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-2928466-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2019-09-24 | — | — | US | disclosed |
| US-9993463-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | HTR5A, HTR1A, HTR3A | FLT3 3104/4885KDR 695/4885AXL 3482/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | FLT3 3152/4885KDR 2824/4885AXL 2044/4885 |
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | MGMT, IDH3A, CYP3A43 | FLT3 1224/4885KDR 4314/4885AXL 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.